Stockscreener 앱 받기
13.80
0.22%
-0.03
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week LowHere's What Happened - MarketBeat
Is Janux Therapeutics Inc a good long term investmentEarnings Call Summaries & Exceptional Return Capital - earlytimes.in
Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) - Finviz
TD Cowen Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
What analysts say about Janux Therapeutics Inc stockHead and Shoulders Patterns & High Yield Trading Signals - earlytimes.in
Janux Therapeutics Pipeline Remains on Track as JANX008 Advances, Wedbush Says - marketscreener.com
Janux Completes Phase 1a Dose-escalation In Phase 1 JANX008 Study; Expansion Cohorts To Commence - Nasdaq
Janux completes phase 1a dose-escalation for EGFR cancer drug By Investing.com - Investing.com UK
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - New Castle News
Here are the most and least likely M&A targets in biotech, according to Truist - Seeking Alpha
Janux Therapeutics Earnings Notes - Trefis
How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily
Why Janux Therapeutics Inc. stock is favored by top institutions2025 Buyback Activity & Free Reliable Trade Execution Plans - Улправда
Day Trade: Will Janux Therapeutics Inc. stock benefit from infrastructure spendingAnalyst Upgrade & AI Powered Market Entry Strategies - Улправда
Why Janux Therapeutics Inc. stock remains resilientQuarterly Risk Review & Step-by-Step Trade Execution Guides - Улправда
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Market Rankings: Is Janux Therapeutics Inc. stock supported by strong fundamentalsDay Trade & Verified High Yield Trade Plans - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Big Money Moves: Is Janux Therapeutics Inc. stock supported by strong fundamentalsWeekly Profit Summary & Technical Buy Zone Confirmations - Улправда
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Why Janux Therapeutics Inc. stock remains a top recommendationMarket Rally & AI Driven Stock Movement Reports - Улправда
Is Janux Therapeutics Inc. stock a contrarian buyMarket Activity Summary & Daily Chart Pattern Signals - Улправда
Buyout Rumor: Why Janux Therapeutics Inc. stock is favored by top institutionsWeekly Profit Report & Capital Efficient Trade Techniques - Улправда
Barclays Maintains Janux Therapeutics (JANX) Overweight Recommendation - Nasdaq
Janux Therapeutics (NASDAQ:JANX) Hits New 12-Month LowHere's What Happened - MarketBeat
Squarepoint Ops LLC Raises Stock Position in Janux Therapeutics, Inc. $JANX - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Barchart.com
Wyckoff Accumulation Phase Possible in National Standard India LimitedBlue Chip Stock Analysis & Low Cost Capital Growth - earlytimes.in
Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 - AOL.com
Janux Therapeutics (NASDAQ:JANX) Reaches New 52-Week LowWhat's Next? - MarketBeat
Stempoint Capital LP Has $2.08 Million Stock Position in Janux Therapeutics, Inc. $JANX - MarketBeat
Jump Financial LLC Grows Stock Holdings in Janux Therapeutics, Inc. $JANX - MarketBeat
(JANX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Janux Therapeutics (JANX) price target decreased by 10.88% to 69.30 - MSN
Janux Therapeutics, Inc. (JANX) Shareholder/Analyst CallSlideshow (NASDAQ:JANX) 2025-12-09 - Seeking Alpha
Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data - Sahm
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test? - Yahoo Finance
Optimistic Buy Rating for Janux Therapeutics Despite Challenges and Promising Market Potential - TipRanks
Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop - Yahoo Finance
Andrew Hollman Meyer Sells 3,333 Shares of Janux Therapeutics (NASDAQ:JANX) Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Janux Therapeutics price target lowered to $32 from $80 at Clear Street - MSN
Janux Therapeutics falls -48.4% - MSN
Janux Therapeutics' (JANX) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Insider Sell: Andrew Meyer Sells Shares of Janux Therapeutics In - GuruFocus
Janux Therapeutics CBO Meyer Andrew Hollman Sells Shares - TradingView — Track All Markets
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound - Stocktwits
Janux Therapeutics Sees Unusually Large Options Volume (NASDAQ:JANX) - MarketBeat
Analysts Unfazed By Janux’s Weaker Prostate Cancer Results - Citeline News & Insights
12/2/2025 Market UpdateWinners: XHLD, TLRY, HPPLosers: SONN, JANX, ABTCS&P 500: 0% - Trefis
Janux Therapeutics (NASDAQ:JANX) Sets New 1-Year Low After Analyst Downgrade - MarketBeat
Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data - Seeking Alpha
Stocks Edge Higher As Traders Wait For Key Inflation Data - Finimize
Bank of America Issues Pessimistic Forecast for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Janux tanks despite claiming positive trial results for JANX007 in mCRPC - The Pharma Letter
Janux Therapeutics (NASDAQ:JANX) Given New $150.00 Price Target at Cantor Fitzgerald - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Pfizer (PFE) and Janux Therapeutics Inc (JANX) - The Globe and Mail
0.90%
자본화:
|
볼륨(24시간):